Journal of Microbiology and Biotechnology

  • 제33권1호
  • /
  • Pages.35-42
  • /
  • 2023
  • /
  • 1017-7825(pISSN)
  • /
  • 1738-8872(eISSN)
한국미생물·생명공학회 (The Korean Society for Microbiology and Biotechnology)
권호 표지
DOI QR코드

DOI QR Code

Protective Role of the Toll-Like Receptor 5 Agonist KMRC011 against Murine Colitis Induced by Citrobacter rodentium and Dextran Sulfate Sodium

  • Jun-Young Kim (Department of Laboratory Animal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Sun-Min Seo (Department of Laboratory Animal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Han-Woong Kim (Department of Laboratory Animal Medicine, College of Veterinary Medicine, Konkuk University) ;
  • Woo-Jong Lee (CONNEXT Co. Ltd) ;
  • Yang-Kyu Choi (Department of Laboratory Animal Medicine, College of Veterinary Medicine, Konkuk University)
  • 투고 : 2022.09.29
  • 심사 : 2022.11.10
  • 발행 : 2023.01.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

This study aimed to identify the therapeutic ability of a novel toll-like receptor (TLR) 5 agonist, KMRC011, on ulcerative colitis induced by Citrobacter rodentium and dextran sulfate sodium in a C57BL/6N mouse model. Ulcerative colitis was induced in the mice by the oral administration of 1% dextran sulfate sodium in sterile drinking water for seven days ad libitum, followed by C. rodentium infection on the seventh day by intra-gastric administration (DSS-CT group). KMRC011 was administered intramuscularly at both 24 h and 15 min before (Treatment 1 group), and at both 15 min and 24 h after (Treatment 2 group) the C. rodentium infection. The length of the large intestine and histopathological counts were significantly greater and mucosal thickness was significantly thinner in the Treatment 1 group compared to the DSS-CT and Treatment 2 groups. Il-6 and Il-10 mRNA expression levels were upregulated, while Ifn-γ and Tnf-α mRNA expression levels were significantly downregulated in the Treatment 1 group, compared to the DSS-CT group. NF-κB p65 expression level was elevated due to ulcerative colitis in the DSS-CT group, but was significantly downregulated in the Treatment 1 group. Overall, KMRC011 showed protective effects against murine colitis by inhibiting NF-κB signaling.

키워드

과제정보

This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIT) (No. 2020R1A2C2005898) and the Civil-Military Technology Cooperation Program (14-CM-EB-09; NTIS 1695004819).

참고문헌

  1. Schirmer M, Garner A, Vlamakis H, Xavier RJ. 2019. Microbial genes and pathways in inflammatory bowel disease. Nat. Rev. Microbiol. 17: 497-511.  https://doi.org/10.1038/s41579-019-0213-6
  2. Cucchiara S, Stronati L, Aloi M. 2012. Interactions between intestinal microbiota and innate immune system in pediatric inflammatory bowel disease. J. Clin. Gastroenterol. 46: S64-S66.  https://doi.org/10.1097/MCG.0b013e31826a857f
  3. Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, et al. 2010. Colitis induced in mice with dextran sulfate sodium (DSS) is mediated by the NLRP3 inflammasome. Gut 59: 1192-1199.  https://doi.org/10.1136/gut.2009.197822
  4. Shanahan F. 2001. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology 120: 622-635.  https://doi.org/10.1053/gast.2001.22122
  5. Levin A, Shibolet O. 2008. Toll-like receptors in inflammatory bowel disease-stepping into uncharted territory. World J. Gastroenterol. 14: 5149-5153.  https://doi.org/10.3748/wjg.14.5149
  6. Neurath M, Fuss I, Strober W. 2000. TNBS-colitis. Int. Rev. Immunol. 19: 51-62.  https://doi.org/10.3109/08830180009048389
  7. Wirtz S, Neurath MF. 2007. Mouse models of inflammatory bowel disease. Adv. Drug Deliv. Rev. 59: 1073-1083.  https://doi.org/10.1016/j.addr.2007.07.003
  8. Perse M, Cerar A. 2012. Dextran sodium sulphate colitis mouse model: traps and tricks. J. Biomed. Biotechnol. 2012: 718617. 
  9. Wirtz S, Neufert C, Weigmann B, Neurath MF. 2007. Chemically induced mouse models of intestinal inflammation. Nat. Protoc. 2: 541-546.  https://doi.org/10.1038/nprot.2007.41
  10. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, Nakaya R. 1990. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702.  https://doi.org/10.1016/0016-5085(90)90290-H
  11. Chassaing B, Aitken JD, Malleshappa M, Vijay-Kumar M. 2014. Dextran sulfate sodium (DSS)-induced colitis in mice. Curr. Protoc. Immunol. 104: Unit-15.25. 
  12. Alipour M, Lou Y, Zimmerman D, Bording-Jorgensen MW, Sergi C, Liu JJ, et al. 2013. A balanced IL-1beta activity is required for host response to Citrobacter rodentium infection. PLoS One 8: e80656. 
  13. Luperchio SA, Schauer DB. 2001. Molecular pathogenesis of Citrobacter rodentium and transmissible murine colonic hyperplasia. Microbes Infect. 3: 333-340.  https://doi.org/10.1016/S1286-4579(01)01387-9
  14. Schauer DB, Zabel BA, Pedraza IF, O'Hara CM, Steigerwalt AG, Brenner DJ. 1995. Genetic and biochemical characterization of Citrobacter rodentium sp. J. Clin. Microbiol. 33: 2064-2068.  https://doi.org/10.1128/jcm.33.8.2064-2068.1995
  15. Deng W, Li Y, Vallance BA, Finlay BB. 2001. Locus of enterocyte effacement from Citrobacter rodentium: sequence analysis and evidence for horizontal transfer among attaching and effacing pathogens. Infect. Immun. 69: 6323-6335.  https://doi.org/10.1128/IAI.69.10.6323-6335.2001
  16. Mundy R, MacDonald TT, Dougan G, Frankel G, Wiles S. 2005. Citrobacter rodentium of mice and man. Cell Microbiol. 7: 1697-1706.  https://doi.org/10.1111/j.1462-5822.2005.00625.x
  17. Song WS, Kim JH, Choi CM, Lee WJ, Yoon SI. 2019. TLR5 binding and activation by KMRC011, a flagellin-derived radiation countermeasure. Biochem. Biophys. Res. Commun. 508: 570-575.  https://doi.org/10.1016/j.bbrc.2018.11.080
  18. Xavier RJ, Podolsky DK. 2007. Unravelling the pathogenesis of inflammatory bowel disease. Nature 448: 427-434.  https://doi.org/10.1038/nature06005
  19. Kim JY, Park JH, Seo SM, Park JI, Jeon HY, Lee HK, et al. 2019. Radioprotective effect of newly synthesized toll-like receptor 5 agonist, KMRC011, in mice exposed to total-body irradiation. J. Radiat. Res. 60: 432-441.  https://doi.org/10.1093/jrr/rrz024
  20. Xu Y, Dong H, Ge C, Gao Y, Liu H, Li W, et al. 2016. CBLB502 administration protects gut mucosal tissue in ulcerative colitis by inhibiting inflammation. Ann. Transl. Med. 4: 301. 
  21. Park JI, Seo SM, Park JH, Jeon HY, Kim JY, Ryu SH, et al. 2018. A murine colitis model developed using a combination of dextran sulfate sodium and Citrobacter rodentium. J. Microbiol. 56: 272-279.  https://doi.org/10.1007/s12275-018-7504-x
  22. Singh K, Chaturvedi R, Barry DP, Coburn LA, Asim M, Lewis ND, et al. 2001. The apolipoprotein E-mimetic peptide COG112 inhibits NF-kappaB signaling, proinflammatory cytokine expression, and disease activity in murine models of colitis. J. Biol. Chem. 286: 3839-3850.  https://doi.org/10.1074/jbc.M110.176719
  23. Kitajima S, Takuma S, Morimoto M. 2000. Histological analysis of murine colitis induced by dextran sulfate sodium of different molecular weights. Exp. Anim. 49: 9-15.  https://doi.org/10.1538/expanim.49.9
  24. Hibi T, Ohara M, Watanabe M, Kanai T, Takaishi H, Hayashi A, et al. 1993. Interleukin 2 and interferon-gamma augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis. Gut 34: 788-793.  https://doi.org/10.1136/gut.34.6.788
  25. Raab Y, Gerdin B, Ahlstedt S, Hallgren R. 1993. Neutrophil mucosal involvement is accompanied by enhanced local production of interleukin-8 in ulcerative-colitis. Gut 34: 1203-1206.  https://doi.org/10.1136/gut.34.9.1203
  26. Yu D, Zhu H, Liu Y, Cao J, Zhang X. 2009. Regulation of proinflammatory cytokine expression in primary mouse astrocytes by coronavirus infection. J. Virol. 83: 12204-12214.  https://doi.org/10.1128/JVI.01103-09
  27. Moore KW, Malefyt RD, Coffman RL, O'Garra A. 2001. Interleukin-10 and the interleukin-10 receptor. Annu. Rev. Immunol. 19: 683-765.  https://doi.org/10.1146/annurev.immunol.19.1.683
  28. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, et al. 2005. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129: 550-564.  https://doi.org/10.1016/j.gastro.2005.05.002
  29. Zhang H, Chen W. 2017. Interleukin 6 inhibition by triptolide prevents inflammation in a mouse model of ulcerative colitis. Exp. Ther. Med. 14: 2271-2276.  https://doi.org/10.3892/etm.2017.4778
  30. Reinisch W, Gasche C, Tillinger W, Wyatt J, Lichtenberger C, Willheim CM et al. 1999. Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am. J. Gastroenterol. 94: 2156-2164.  https://doi.org/10.1111/j.1572-0241.1999.01288.x
  31. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. 2011. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim. Biophys. Acta 1813: 878-88.  https://doi.org/10.1016/j.bbamcr.2011.01.034
  32. Schreiber S, Nikolaus S, Hampe J. 1998. Activation of nuclear factor kappa B in inflammatory bowel disease. Gut 42: 477-484.  https://doi.org/10.1136/gut.42.4.477
  33. Andresen L, Jorgensen VL, Perner A, Hansen A, Eugen-Olsen J, Rask-Madsen J. 2005. Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and ulcerative colitis. Gut 54: 503-509.  https://doi.org/10.1136/gut.2003.034165
  34. Assas BM, Levison SE, Little M, England H, Battrick L, Bagnall J, et al. 2017. Anti-inflammatory effects of infliximab in mice are independent of tumour necrosis factor α neutralization. Clin. Exp. Immunol. 187: 225-233.  https://doi.org/10.1111/cei.12872
  35. Guidi L, Costanzo M, Ciarniello M, De Vitis I, Pioli C, Gatta L, et al. 2005. Increased levels of NF-κB inhibitors (IκBα and IκBγ) in the intestinal mucosa of crohn's disease patients during infliximab treatment. Int. J. Immunopathol. Pharmacol. 18: 155-164.  https://doi.org/10.1177/039463200501800116
  36. Dou W, Zhang J, Sun A, Zhang E, Ding L, Mukherjee S, et al. 2013. Protective effect of naringenin against experimental colitis via suppression of Toll-like receptor 4/NF-kappaB signalling. Br. J. Nutr. 110: 599-608. https://doi.org/10.1017/S0007114512005594